2020 American Transplant Congress
Eplet Mismatch Imputed from HLA Serotype-Level Data Can Improve Risk Stratification for Kidney Allograft Loss
*Purpose: HLA-Epitope mismatch improves risk stratification following kidney transplantation. Based on population data, high resolution HLA types required for epitope prediction can be imputed based…2020 American Transplant Congress
A Multicenter Analysis of the Proportion and Pattern of Unexplained HLA Antibodies in Kidney Recipients without a History of Sensitization
*Purpose: Previous studies report a high prevalence of unexplained antibody reactivities on the single antigen bead (SAB) test. In a contemporary multicenter cohort of non-sensitized…2020 American Transplant Congress
HLA Specific Antibody Levels after EDTA Treatment in CDC Crossmatch Positive and Negative Sera with Known Donor-Specific Antibodies
*Purpose: Ethylenediaminetetraacetic acid (EDTA) treatment of serum samples overcomes the prozone effect that may interfere with solid phase HLA specific antibody analyses. In patients with…2020 American Transplant Congress
The Clinical Relevance of cPRA in 0-ABDRDQ Mismatched Kidney Transplants
*Purpose: The clinical relevance of immune sensitization as measured by cPRA in kidney transplantation remains uncertain.*Methods: We identified 4,057 adult, first, kidney only transplant recipients…2019 American Transplant Congress
Characterization of Circulating T-cell Specific Exosomes during Acute Rejection in Murine Heart Transplantation Model
*Purpose: Exosomes are nanoparticles (30-200nm) released by many cell types. They carry nucleic acid and proteins that may reflect conditional changes in their tissue counterparts.…2019 American Transplant Congress
Donor-Recipient HLA Mismatched Peptides Calculated by PIRCHE Algorithm Associate with De Novo Donor-Specific Cellular and Humoral Alloreactivity and Predicts Inferior Graft Outcome
*Purpose: PIRCHE-II algorithm predicts mismatched donor-derived HLA peptides number presented on recipient HLAclass-II molecules to recipient T-cells (indirect pathway of allorecognition) and has been associated…2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…2019 American Transplant Congress
Patients with Immunological Diseases or on Peritoneal Dialysis Are Prone to False Positive Flow Cytometry Cross Match
*Purpose: Despite implementation of virtual cross matches, flow cytometry cross matches (FCXM) are still used by many transplant centers to determine immunological risk prior to…2019 American Transplant Congress
Correlation of Crossmatch Predictions with Actual Results and Clinical Outcomes
1Vanderbilt University Medical Center, Nashville, TN, 2Dialysis Clinic, Inc, Nashville, TN
*Purpose: Flow cytometry crossmatching (FXM) is recognized as a valuable tool to assess immunological risk prior to renal transplantation. The increased resolution in HLA typing…2019 American Transplant Congress
Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation
*Purpose: Plasmapheresis in combination with immunoglobulin and rituximab is often used to induce accommodation in ABO-incompatible (ABOi) living-donor transplantation; however, this regimen cannot be applied…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »